Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week

Journal Scan / Research · April 29, 2022

Nintedanib or Placebo Added to Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Muscle-Invasive Bladder Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial
Lancet Oncol 2022 Apr 11;[EPub Ahead of Print], SA Hussain, JF Lester, R Jackson, M Gornall, M Qureshi, A Elliott, SJ Crabb, RA Huddart, N Vasudev, AJ Birtle, J Worlding, ND James, O Parikh, M Vilarino-Varela, R Alonzi, MD Linch, IB Riaz, JWF Catto, T Powles, RJ Jones

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading